Andrea Arroyo
Adult Health · Baltimore, MDNPI 1548656655
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,829 of the $7,728 with a category attached, or 88.4%. It is spread thinly across 35 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $4,100 and has fallen 90.9% since, to $373 in 2024. Among adult health clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 342 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Biohaven Pharmaceuticals, Inc.$1K
- Novo Nordisk$755
- Lilly USA, LLC$678
- AstraZeneca$609
- GSK$427
- plus $3K from 29 others
What the payments were for
- Consulting fees$80010%
- Food & beverage$6,82988%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 63 | $1,402 |
| Biohaven Pharmaceuticals, Inc. | 15 | $1,156 |
| Novo Nordisk | 32 | $755 |
| Lilly USA, LLC | 45 | $678 |
| AstraZeneca | 27 | $609 |
| GSK | 20 | $427 |
| Amarin Pharma, Inc. | 18 | $282 |
| Johnson & Johnson | 8 | $273 |
| Boehringer Ingelheim | 11 | $176 |
| Astellas Pharma US Inc | 5 | $158 |
| Exact Sciences | 6 | $152 |
| Sunovion Pharmaceuticals Inc. | 8 | $147 |
| Jazz Pharmaceuticals Inc. | 2 | $142 |
| Grifols USA, LLC | 8 | $133 |
| Merck | 8 | $131 |
| Novartis | 7 | $121 |
| E.r. Squibb & Sons, L.L.C. | 6 | $105 |
| Bayer | 4 | $91 |
| Sanofi-aventis U.S. LLC | 6 | $85 |
| Pfizer | 5 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $77 |
| Zealand Pharma US, Inc. | 3 | $76 |
| Amgen(2 entities) | 4 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $63 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| Teva Pharmaceuticals USA, Inc. | 4 | $53 |
| Esperion Therapeutics, Inc. | 3 | $45 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Currax Pharmaceuticals LLC | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Corium, LLC | 1 | $21 |
| Dynavax Technologies Corporation | 1 | $20 |
| Bausch Health US, LLC | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$924
- VRAYLAR$248
- UBRELVY$235
- SUNOSI$125
- QULIPTA$125
- TRELEGY ELLIPTA$125
- FARXIGA$122
- Ozempic$122
- XARELTO$117
How this compares
$7,728 in reported general payments places this provider in the 95th percentile of 542 adult health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 13 | $6,377 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $3,737 |
| Potassium Chloride | 25 | $1,848 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $1,235 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,048 |
| Rosuvastatin Calcium | 31 | $1,005 |
| Atorvastatin Calcium | 110 | $804 |
| Metoprolol Succinate | 25 | $654 |
| Levothyroxine Sodium | 47 | $589 |
| Levetiracetam | 18 | $533 |
| SynthroidLevothyroxine Sodium | 29 | $518 |
| Montelukast Sodium | 28 | $475 |
| Amlodipine Besylate | 81 | $449 |
| Omeprazole | 32 | $409 |
| Gabapentin | 47 | $380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $158 | $6,37713 claims |
| AbbVieCombigan, Synthroid | $1,402 | $4,25446 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 542 adult health providers in Maryland.
Other adult health in Baltimore
- Christopher RobersonBaltimore$180K
- Amit DhirBaltimore$97K
- Brendon BowerBaltimore$64K
- Caitlin NassBaltimore$46K
- Sarah RileyBaltimore$24K
- Monica LovinsBaltimore$18K
- Elizabeth ChandlerBaltimore$17K
- Clifton DawsonBaltimore$14K
- Selina YeasminBaltimore$8K
- Kathleen CostelloBaltimore$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.